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Abstract
Background: Oral glutamine decreases whole body protein breakdown in Duchenne muscular dystrophy (DMD). We
evaluated the functional benefit of 4 months oral glutamine in DMD.
Methodology/Principal Findings: 30 ambulant DMD boys were included in this double-blind, randomized crossover trial
with 2 intervention periods: glutamine (0.5 g/kg/d) and placebo, 4 months each, separated by a 1-month wash-out, at 3
outpatient clinical investigation centers in France. Functional benefit was tested by comparing glutamine versus placebo on
change in walking speed at 4 months. Secondary outcome measures were: 2-minute walk test, work, power, muscle mass
(urinary creatinine), markers of myofibrillar protein breakdown (urinary 3-methyl-histidine/creatinine), serum creatine
phospho-kinase, body composition (fat free mass, fat mass percentage), safety and oral nutrient intake. There was no
improvement in the primary end point (walking speed) or in secondary measures of muscle function (2-minute walk test,
work, power) in the glutamine group compared with placebo. However, subjects receiving glutamine or placebo showed no
deterioration in functional measures over the course of the 9-month trial. No differences in muscle mass, markers of protein
breakdown or serum creatine phosho-kinase were observed, except for a blunted increase in fat free mass in the glutamine
group which led to a greater increase in fat mass percentage. Glutamine was safe and well-tolerated.
Conclusions: This trial did not identify additional benefit of 4 months oral glutamine over placebo on muscle mass or
function in ambulatory DMD boys. Although apparently safe, current data cannot support routine supplementation in this
population as a whole, until further research proves otherwise.
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Introduction
Duchenne muscular dystrophy (DMD) is a serious X-linked
disease caused by mutations in the gene that encodes the
cytoskeletal protein dystrophin [1]. The absence of dystrophin is
associated with a progressive and severe loss of muscle mass and
function. To date, there is no cure, emphasizing the need for the
development of therapies that target downstream events in the
pathologic progression of DMD muscle wasting. Although
corticosteroids have been proven effective in preserving muscle
mass and function in DMD [2], some physicians and families are
reluctant to place children on this therapy owing to adverse effects.
Nutritional therapies in conjunction with drug, cellular or gene
therapy might provide another approach [3,4]. However much of
the data showing benefits are based on experimental evidence in
the mdx mouse model [3–15], and few randomized controlled trials
(RCT) have been conducted in DMD patients [16–19].
Glutamine (Gln) is a non-essential amino acid that is mainly
produced and stored in skeletal muscle [20]. Evidence for its
efficacy is supported by clinical benefits in several catabolic states
[21]. Whole body Gln turnover is decreased in DMD compared to
control children, resulting from a decrease in estimates of Gln de
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production. Also because in protein-wasting situations (e.g. DMD)
the intramuscular Gln concentration is low [23], Gln might be
considered a conditionally essential amino acid. Acute oral Gln
administered continuously for 5 hours decreased whole body
protein breakdown in DMD boys [24]. This protein-sparing effect
persisted when Gln was administered daily using the same dose
(0.5 g/kg/d) over a longer period (10 days) [19]. Based on this
evidence, the hypothesis was that supplemental Gln would slow
disease progression and therefore provide functional benefit. To
evaluate functional benefit, we compared change in walking speed
after 4 months Gln versus placebo in ambulant DMD boys.
Secondary endpoints were: 2-minute walk test (2-MWT), work,
power, muscle mass, markers of myofibrillar protein breakdown,
serum creatine phospho-kinase (CPK) and body composition.
Safety and tolerance were also assessed.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Participants
This was a randomized, placebo-controlled, double-blind,
crossover trial of oral Gln versus placebo in ambulant DMD boys
in 3 participating clinical investigation centers across France. The
protocol was approved by the Paris-Bichat Ethics Committee
(Comite ´ Consultatif pour la Protection de la Personne dans la
Recherche Biome ´dicale) and conducted according to Declaration
of Helsinki principles. The statement from the Ethics Committee
indicating their approval of the research is available as supporting
information; see Statement S1. Subjects were selected on the basis
of the following eligibility criteria: Pediatric neurologist diagnosis
of DMD by clinical history, muscle biopsy (absence of dystrophin
confirmed by immunohistochemistry or Western blot) and
molecular biology, as well as the ability to walk $170 m.
Exclusion criteria included: wheelchair dependency, body weight
.60 kg, hepatic or renal insufficiency, or surgery scheduled in the
year following the first visit. Subjects were recruited among those
followed in multidisciplinary outpatient facilities from University
hospitals in Paris, Poitiers and Lille, France. All participating
families gave their written informed consent after a thorough
explanation of the study protocol to both the parents and the
children. A sample of a patient consent form (parent) and a patient
assent form (children) are available as supporting information; see
Form S1 and Form S2.
Randomization and Interventions
Randomization and blinding were coordinated through the
De ´partement de la Recherche Clinique et du De ´veloppement of
the Assistance Publique-Ho ˆpitaux de Paris and a central pharmacy
(Agence Ge ´ne ´rale des Equipements et Produits de Sante ´; AGEPS;
Paris, France) who did not participate in the evaluation of study
subjects. This included computerized generation of the allocation
schedule in blocks of 6 subjects and blinded disbursement of
treatment in numbered containers. The code was located at the
De ´partement de la Recherche Clinique et du De ´veloppement
during the trial and until the completion of statistical analysis. No
adverse events during the trial required breaking the code.
Individual subjects were enrolled by the site investigator and were
randomly assigned in a double blind crossover manner to 4
months of taking oral Gln (0.5 g/kg/d) followed by 4 months of
taking placebo (maltodextrin; of equal weight) or vice versa. The
two 4-month periods were separated by a 1-month wash-out. The
order of treatment allocation was randomized. Participants,
investigators, physicians, assessors and data analysts were blinded
throughout the trial to the order of treatment assignment. The Gln
dose (0.5 g/kg/d) was selected based on previous studies in DMD
boys [24] and in healthy humans [25,26] that showed a 2-fold
increase in plasma Gln concentrations during Gln administration.
This same dose decreased whole body protein degradation in
DMD boys during Gln administration [24], which persisted
24 hours after supplementation ceased, while plasma Gln
concentrations had returned to normal [19].
L-Glutamine and placebo were prepared by a central pharmacy
(AGEPS) and kept by the pharmacist, who was not familiar with
the subjects. The 2 supplements were prepared as powders of
identical taste, odor and appearance and were flavored with
banana, caramel and artificial sweetener (Aspartame; AGEPS).
Supplements were identically packaged in 5 g sachets and
disbursed to participants in 2 individual boxes (1 box representing
a 1-month supply of Gln or placebo) which contained a known
number of sachets in excess of the number required for 2 months
supplementation at visits 0, 2, 5, 7 months. The children and their
families were instructed to take Gln or placebo once per day in the
morning mixed with water or yogurt. Compliance was assessed by
the number of used and unused sachets returned at each visit
following supplementation.
Outcomes and follow-up
Based on the hypothesis that supplemental Gln would slow
disease progression and therefore provide functional benefit, we
compared change in walking speed after 4 months Gln versus
placebo in ambulant DMD boys. The primary outcome measure
was change in walking speed (m/s) measured in seconds taken to
walk a specified distance (170 m) at a comfortable pace [27].
Secondary outcome measures included change in the following
variables: 2-MWT (m) [27,28], work (kcal), power (kcal/s), body
composition, muscle mass (24-h urinary creatinine excretion),
serum CPK (a non-specific indicator of sarcolemmal integrity),
urinary excretion of 3-methyl-histidine/creatinine ratio (a marker
of myofibrillar protein breakdown) [29] and oral nutrient intake.
Incidence and severity of adverse events were assessed by reported
signs and symptoms as well as physical examinations, vital signs
and biochemical parameters. The children were evaluated every 2
months during period 1 (0, 2, 4 months) and period 2 (5, 7, 9
months) at one of the 3 clinical investigations centers (Paris,
Poitiers or Lille). In total 6 visits were made by each child over the
9 month study.
Fasting blood samples were collected at 0, 2, 4, 5, 7, 9 months.
Safety assessment including physical exam, vital signs measure-
ments and biochemical parameters were performed at 0, 2, 4, 5, 7,
9 months and medical treatment was provided when required.
Body composition was estimated by using monofrequency
(50 kHz) bioelectrical impedance analysis (BIA; 101 Q; RJL
systems, Clinton Township, MI or Quantum/S; Akern SRL,
Pontassieve, Italy) at 0, 2, 4, 5, 7, 9 months and dual-energy X-ray
absorptiometry (DXA; Lunar Corporation, Madison, WI or
Hologic Discovery, Bedford, MA) at 4 and 9 months. Subjects
were studied in the morning after an overnight fast and were
instructed to void before being measured. Three consecutive 24 h
urine collections were performed prior to each visit at 0, 2, 4, 5, 7,
9 months. Muscle mass was estimated from 24 h urinary
creatinine excretion, assuming that 1 g per day of urinary
creatinine excretion represents 20 kg of muscle mass [30]. Urinary
3-methyl-histidine concentration was measured using an automat-
ed unit and expressed relative to creatinine. Biochemistry was
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nutrient intake was assessed by a registered dietitian using a 2-d
food record taken at visits 4 and 9 months. To ensure validity and
quality of the data, monitoring was performed at each site during
the trial and at study completion.
Statistical analysis
Sample size estimates were based on the response to the primary
outcome variable (walking speed in m/s). Previous data showed
that walking speed for children with muscular dystrophy was
0.9560.15 m/s [31]. For a crossover study, requiring a 10%
increase in walking speed after 4 months Gln versus placebo, we
calculated that 30 subjects were needed to have an 80% power to
detect a difference at an a of 5%.
Data were double entered. Analysis was carried out by a blinded
statistician using SAS version 9.1 (SAS Institute Inc., Cary, NC).
Data are presented as medians (25% ; 75% quartiles (Q1 ; Q3)) or
means (6standard deviation (6SD)) for continuous variables and
as proportions (percentages) for categorical variables. Inter-group
comparisons were performed using Student’s t test for normally
distributed data or Wilcoxon’s rank test for non-parametric
distributions and intra-group comparisons were performed using
paired Student’s t test or Wilcoxon’s signed rank test as
appropriate. The primary analysis of the data was on the primary
outcome variable, change in walking speed. For a crossover design
we evaluated treatment and order effects as well as the interaction.
The effect of treatment with Gln was assessed using repeated-
measures analysis of variance. The same approach was used to
analyze the secondary outcome variables. Normality of residuals
and absence of heteroscedasticity were verified, otherwise
logarithmic or square root transformations were applied to the
dependent variable. Significance was set at p,0.05.
Results
Participants
Figure 1 shows the trial profile. The families of 34 boys were
screened, of whom 30 boys aged 2 to 10 y were recruited.
Agreement to participate was not received by 3 families and 1 boy
did not meet one of the inclusion criteria because of body weight
.60 kg. Of 30 boys randomized, all completed the study. One
subject was not analyzed for the primary outcome, because he was
unable to walk $170 m (secondary to gastroenteritis) at the 4
month visit during the placebo phase. Subjects were recruited
between February 2006 and February 2007. The study was
completed in November 2007. Baseline characteristics of the study
population are presented in Table 1. Five boys were on
corticosteroids during the trial and none were taking other
potentially anabolic co-interventions or supplements (e.g. creatine).
Outcomes and estimation
There was no functional improvement, based on the primary
outcome measure (walking speed) during 4 months Gln treatment
compared to placebo (Table 2). The same pattern was seen for 2-
MWT, work and power, without any significant improvement
after 4 months Gln treatment (Table 2). Notably the placebo
group did not show deterioration of functional measures over a 4-
month period (Table 2). Moreover, subjects overall did not show
deterioration of functional measures over the course of the 9-
month study. Mean walking speed (6SD) remained stable from
0.9 m/s (60.2) at baseline to 0.8 m/s (60.3) at 9 months
(p=0.78; paired samples t test). Similarly, the 2-MWT did not
differ from baseline (103.9 m (620.4)) to the end of study, at 9
months (98.9 m (628.1)) (p=0.39; paired samples t test).
Over the 9-month trial, there was a significant increase in fat
free mass as measured by BIA and fat mass percentage as
measured by BIA and DXA. Median (Q1 ; Q3) fat free mass
increased from 16.2 kg (14.4 ; 19.2) at baseline to 17.4 kg (15.0 ;
19.5) at 9 months (p,0.0001; Wilcoxon’s signed rank test) and
percentage fat mass increased from 11.3% (4.7 ; 17.2) at baseline
to 16.1% (9.9 ; 21.8) at 9 months (p,0.0001; Wilcoxon’s signed
rank test) in subjects overall. The increase in fat free mass was
significantly less with 4 months Gln treatment versus placebo
(Table 2) and an order effect was observed (p=0.001). In turn, the
increase in percentage fat mass as measured by BIA was
significantly greater with Gln treatment (Table 2). Similarly,
median percentage fat mass (Q1 ; Q3) measured by DXA was
20.2% (14.1 ; 27.4) after 4 months Gln treatment and differed
from placebo (18.5% (14.1 ; 28.8)) (p=0.03; variance analysis,
square root transformation). Median muscle mass (Q1 ; Q3)
estimated by 24 h urinary creatinine excretion decreased from
4.1 kg (3.0 ; 5.1) at baseline to 3.5 kg (2.6 ; 4.1) at 9 months
(p,0.0001; Wilcoxon’s signed rank test). However, the change in
muscle mass with 4 months Gln treatment was not different from
placebo (Table 2). Consistent with muscle mass, markers of
myofibrillar protein breakdown (3 methyl-histidine/creatinine
ratio in urine) and serum CPK were not affected by Gln treatment
compared with placebo (Table 2). Furthermore, the 24 h excretion
of 3 methyl-histidine in urine was not affected by 4 months Gln
treatment (p=0.25).
The families of 15 subjects (50%) considered the child’s
condition improved during the 4 months Gln treatment, whereas
12 families (40%) found that their child’s condition improved
during the placebo phase. The families of 3 subjects (10%) found
the child’s condition equivalent in both phases.
There was no significant difference in oral nutrient intake
during 4 months Gln treatment compared with 4 months placebo,
as assessed by median (Q1 ; Q3) total daily energy intake
(1526 kcal (1399 ; 1758) for the placebo group compared with
1529 kcal (1331 ; 1766) for the Gln group) or percentage daily kcal
from protein (16% (15 ; 19) for the placebo group compared with
17% (14 ; 19) for the Gln group). Compliance as assessed by the
number of used and unused sachets returned was also similar
between Gln treatment and placebo.
Safety and Tolerability
Gln and placebo were safe and well-tolerated by most of the
children with no significant difference in side-effect profiles or
biochemical parameters between groups. Adverse events reported
during the 4-months Gln and placebo treatment periods included:
gastroenteritis (Gln, n=1; placebo, n=2), urticaria (Gln, n=1;
placebo, n=0), allergic reaction (Gln, n=0; placebo, n=1),
nervousness (Gln, n=1; placebo, n=0), rhinitis (Gln, n=0;
placebo, n=1) and pharyngitis (Gln, n=0; placebo, n=1).
Discussion
Interpretation
Although experimental data in mdx mice [9,11] and short term
clinical studies on protein metabolism [19,24], suggest a role for
Gln in the treatment of DMD, the present randomized crossover
trial did not show improved muscle function when oral Gln
administered for 4 months was compared to placebo in
ambulatory DMD boys. Only 1 previous RCT tested the efficacy
of Gln in DMD boys [17], using a parallel trial to compare 6-
months oral Gln (0.6 g/kg/d) (n=19) with placebo (n=16) and
showed no significant effects on manual or quantitative measures
of muscle strength. This previous trial showed significantly less
Glutamine in Duchenne Children
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(,7 y), however the significant age-related results were based on
an unplanned subgroup analysis in a small group of DMD boys
[17].
In the present trial, we assessed muscle function by walking
speed. We employed a functional measure as the primary
outcome, because timed function testing is a clinically relevant
trial endpoint in DMD [32]. Previous data suggest that timed
functional tests are reliable measures that should be used in
multicenter trials in ambulant DMD children to obtain maximum
power and sensitivity [32,33]. Few trials have demonstrated a
functional benefit in DMD. A previous RCT of prednisone in
DMD showed improvement in function to peak at 3 months [2].
The present trial however did not detect arrest of disease
progression or minimal improvement in function with 4 months
Gln over placebo. We used timed functional testing which is more
reliable [32] and sensitive to determine the extent of disease
progression in DMD [33] than muscle force measurement.
Furthermore, timed walk tests have been shown to have high
test-retest reliability in a range of patients with neurological
disorders (intraclass correlation coefficient of 0.97) [27] and in
children with cystic fibrosis (coefficient of variation of 2.6%) [34].
Our findings that functional measures did not deteriorate during
the 4-month placebo phase, or over the course of 9 months, were
Figure 1. Flow of participants. Each 4 month intervention phase was separated by a washout period of at least 1 month.
doi:10.1371/journal.pone.0005448.g001
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present crossover trial was sufficiently powered to detect a 10%
increase in walking speed after 4 months Gln compared to
placebo. We however did not consider that children respond more
strongly to placebo in RCTs than adults do, according to a recent
meta-analysis in drug resistant partial epilepsy [36]. Thus the
greater placebo effect in children could have narrowed the
expected effect size of Gln treatment. Furthermore, the finding
that the families of 40% of subjects reported that their child’s
condition improved during the placebo phase (versus 50% during
Gln treatment) also supports a placebo effect by proxy, which has
been suggested in younger populations, since parents play an
important role in reporting the outcome of their affected child
[36]. Future trials might consider including a subject group
receiving no intervention or a longer baseline period, to measure
the placebo effect in DMD children.
In the present trial, urinary excretion of 3-methyl-histidine/
creatinine ratio was not affected by 4 months Gln, thus the acute
anti-proteolytic effect of Gln may be transient [19,24]. Because
subjects were not on a meat-free diet prior to urine collection, this
analysis is limited. However, there were no differences in oral
protein intake during Gln treatment compared with placebo. Gln
treatment also did not affect serum CPK or muscle mass
(estimated by urinary creatinine excretion), which showed a
similar decrease in the placebo group. Whereas the present study
and previous reports [37] showed that urinary creatinine excretion
progressively decreases with muscle wasting in DMD, we observed
an increase in fat free mass and percentage fat mass (measured by
BIA). This is not surprising, since BIA estimates total body water,
composed of intracellular and extracellular water. Although
reduced muscle mass may contribute to decreased total body
water, the correlation between the 2 variables was reported to be
weak [38,39]. In DMD, muscle mass correlates with intracellular
water and total body potassium, which decline with age and reflect
progression of disease [38]. At variance, exchangeable sodium (or
extracellular water) as well as total body water increase with
growth in DMD [39]. Furthermore, the relative contribution of fat
free mass to body weight in DMD boys is 73% (versus 84% in
control children), which is greater than expected for a group of
patients with an estimated muscle mass relative to body weight of
only 12% (versus 39% in control children) [40]. This discrepancy
might reflect the replacement of potassium-rich muscle by
potassium-poor hydrated connective tissue or an increase in
extracellular water in addition to fat [38,39], producing the
pseudo-hypertrophy well-recognized clinically [39]. Thus, the BIA
method can provide estimates of fat free mass (or total body water)
in DMD [41], but it cannot provide estimates of muscle mass. The
9% increase in fat free mass during the placebo phase was
significantly higher than that observed after Gln treatment (+2%)
which led to a greater increase in percentage fat mass with Gln
treatment. Because the treatment effect was on the borderline of
significance, it is possible that this may have been a chance finding.
Alternatively, it is possible that the increase in fat free mass during
the placebo phase reflects the natural progression of disease. We
also observed an order effect on fat free mass, which could result
from a difference in disease progression between the first and
second phase of the study or a response to treatment that varies
with time.
Generalizability
Although the criteria that we used to select participants were
simple and as broad as possible to be generalized to DMD
patients, Gln may also have different effects depending on the
stage of the disease process [17]. Inclusion of younger children in
which measures of function are difficult to assess objectively [32],
could explain some of the variability in functional measures.
Alternatively, early treatment, before the pathology manifests are
expected to be the most beneficial [42]. Thus younger children
may be more likely to respond to treatment and may represent a
subgroup for which Gln may prove beneficial. Of interest,
subgroup analysis revealed a differential decline in functional
measures in those taking corticosteroids (versus those on no
corticosteroids). For example in boys taking corticosteroids (n=5),
mean walking speed (6SD) decreased from 1.0 m/s (60.1) at
baseline to 0.7 m/s (60.2) at 9 months (p,0.05; paired samples t
test), whereas those not on corticosteroids (n=25) showed no
deterioration in function over time (baseline: 0.8 m/s (60.2)
versus 9 months: 0.8 m/s (60.3)), similar to the cohort as a whole.
There was also a significant effect of Gln treatment on functional
measures in boys taking corticosteroids (p,0.05; variance analysis,
logarithmic transformation). Specifically, boys taking corticoste-
roids showed a significant decline in median walking speed (Q1 ;
Q3) during the placebo phase (pre: 1.0 m/s (0.7 ; 1.0) versus 4
months: 0.6 m/s (0.6 ; 0.7)), whereas walking speed remained
stable when corticosteroid-treated boys received Gln treatment for
4 months (pre: 0.9 m/s (0.9 ; 1.0) versus 4 months: 1.0 m/s (0.8 ;
1.0)). Although the findings must be interpreted with caution,
because they derive from an unplanned analysis in a small
subgroup of boys, they might suggest a rationale for Gln
supplementation in conjunction with corticosteroid therapy
[43,44], which needs to be investigated.
Because of the heterogeneity in patients who have this disease,
we used a crossover design where all subjects served as their own
controls. While sharing the strengths of a RCT, the efficient design
also permitted us to use a smaller sample size versus a parallel trial,
which is particularly suitable for rare diseases. Although a problem
with the crossover trial is carry-over, we used a washout period.
And given that whole body Gln turnover is high in adults [26] and
even higher in children [45], with complete renewal in ,24 h
[20], we could assume minimal or no carry-over after 1 month.
Table 1. Baseline Characteristics.
Subjects N=30
Median age, y (Q1 ; Q3) 6.1 (4.6 ; 8.2)
Mean weight, kg (6SD) 19.7 (66.0)
Mean weight, z score (6SD) 20.49 (61.1)
Mean height, cm (6SD) 112.7 (614.5)
Mean height, z score (6SD) 20.14 (61.1)
Mean BMI, kg/m
2 (6SD) 15.2 (61.26)
Prepubescent, n (%) 30 (100%)
Corticosteroid treated, n (%) 5 (16.7%)
Median CPK, U/L (Q1 ; Q3) 13810 (9786 ; 17994)
Median 3MH/Creatinine ratio (Q1 ; Q3) 66 (54 ; 75)
Median muscle mass, kg (Q1 ; Q3) 4.1 (3.0 ; 5.1)
Median fat mass, % (Q1 ; Q3) 12.5 (4.7 ; 17.2)
Median fat free mass, kg (Q1 ; Q3) 16.2 (14.4 ; 19.2)
Median walking speed, m/s (Q1 ; Q3) 0.9 (0.7 ; 1.0)
Median 2-MWT, m (Q1 ; Q3) 103 (89 ; 120)
Q1 25% quartile; Q3 75% quartile; SD standard deviation; BMI body mass index;
CPK creatine phosphokinase; 3-MH 3-methyl-histidine; 2-MWT 2-minute walk
test.
doi:10.1371/journal.pone.0005448.t001
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sequence on the relative treatment responses. Among constraints,
our study required longer intervention and follow-up, since all
subjects received placebo. On the other hand, all children received
a potentially beneficial treatment, which is particularly interesting
for chronic non-curable diseases where patients have few medical
options. The study demonstrates the feasibility of a 9-month
crossover trial, since all subjects completed the trial with good
compliance. Although this was not a safety study and was not
powered to detect significant side effects, the data imply that side
effects were minimal when Gln was administered over 4 months
and no subjects withdrew. Safety of supplementation for longer
durations is beyond the scope of this study.
Overall evidence
The present study provides important information to guide the
practice of medicine and is of broad interest to several disciplines,
including child neurologists, movement disorder specialists and
nutritionists. Apart from corticosteroids [2], treatment options are
limited. DMD patients and their families often resort to alternative
Table 2. Primary and Secondary Outcome Measures.
Placebo Glutamine
Median walking speed, m/s (Q1 ; Q3) { n=29 n=30
Pre 0.8 (0.7 ; 1.0) 0.9 (0.7 ; 1.0)
Endpoint (4 mo) 0.8 (0.6 ; 1.0) 0.9 (0.7 ; 1.0)
Change at 4 mo 0.0 (20.1 ; 0.1) 0.0 (20.1 ; 0.1)
Median 2-MWT, m (Q1 ; Q3) { n=29 n=30
Pre 100.0 (86.0 ; 120.9) 105.5 (89.9 ; 115.2)
Endpoint (4 mo) 101.0 (81.6 ; 113.4) 101.5 (87.0 ; 109.0)
Change at 4 mo 2.0 (216.2 ; 13.3) 22.8 (210.0 ; 2.3)
Median work, kcal (Q1 ; Q3) { n=29 n=30
Pre 16.0 (10.9 ; 25.5) 17.0 (11.2 ; 27.1)
Endpoint (4 mo) 16.3 (12.9 ; 24.4) 18.2 (9.3 ; 24.9)
Change at 4 mo 21.1 (27.1 ; 6.3) 0.7 (25.1 ; 2.0)
Median power, watt (Q1 ; Q3) { n=29 n=30
Pre 157 (117 ; 193) 170 (108 ; 195)
Endpoint (4 mo) 152 (113 ; 195) 159 (118 ; 201)
Change at 4 mo 11 (213 ; 23) 10 (217 ; 20)
Median fat mass, % (Q1 ; Q3) { n=27 n=29
Pre 14.3 (6.2 ; 20.4) 11.3 (5.0 ; 18.8)
Endpoint (4 mo) 14.2 (8.2 ; 22.2) 13.8 (9.9 ; 21.8)
Change at 4 mo * 1.2 (21.6 ; 2.3) 1.9 (20.8 ; 4.9)
Median fat free mass, kg (Q1 ; Q3) { n=27 n=29
Pre 15.9 (14.0 ; 19.3) 16.2 (14.6 ; 20.1)
Endpoint (4 mo) 17.4 (14.9 ; 19.0) 16.6 (14.7 ; 19.6)
Change at 4 mo ** 0.7 (0.2 ; 1.2) 0.4 (20.2 ; 0.7)
Median muscle mass, kg (Q1 ; Q3) { n=27 n=26
Pre 3.9 (3.1 ; 5.2) 3.8 (2.4 ; 4.8)
Endpoint (4 mo) 3.6 (2.3 ; 4.2) 3.2 (2.7 ; 4.1)
Change at 4 mo 20.3 (21.5 ; 0.3) 20.7 (21.1 ; 20.1)
Median CPK, U/L (Q1 ; Q3) { n=30 n=30
Pre 13530 (9140 ; 18186) 12010 (10160 ; 17289)
Endpoint (4 mo) 12740 (8380 ; 18350) 10430 (9160 ; 15929)
Change at 4 mo 2795 (23402 ; 3332) 22010 (24984 ; 1340)
Median 3-MH/creatinine (Q1 ; Q3) { n=25 n=24
Pre 72.0 (61.5 ; 78.0) 68.3 (54.0 ; 79.0)
Endpoint (4 mo) 71.9 (61.6 ; 81.0) 67.0 (57.0 ; 76.0)
Change at 4 mo 20.7 (27.2 ; 8.0) 24.8 (216.7 ; 8.8)
*p,0.05 (glutamine vs placebo, repeated-measures analysis of variance without order effect or interaction).
**p,0.05 (glutamine vs placebo, repeated-measures analysis of variance with order effect).
{Logarithmic transformation.
{Square root transformation.
Q1 25% quartile; Q3 75% quartile; CPK creatine phosphokinase; 3-MH 3-methyl-histidine; 2-MWT 2-minute walk test.
doi:10.1371/journal.pone.0005448.t002
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beneficial. However, the physician/neurologist has little scientific
evidence to base their judgement, given the few methodologically
sound RCTs on nutritional therapies in DMD [16–18]. Although
apparently safe, 4 months Gln supplementation did not prove to
be beneficial compared to placebo, based on muscle mass or
function. Thus, the present RCT cannot support its routine use in
this population as a whole. Better targeting of specific subgroups is
necessary to fully evaluate the presence or absence of benefits.
More precise knowledge is also needed regarding the response to
placebo in DMD children. The present trial has implications for
the design of future clinical trials in DMD children or other
pediatric conditions.
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